Vanguard Asset Management
CLDX icon

Vanguard Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Vanguard Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.61M Hold
49,731
– – ﹤0.01% 1662
2026
Q2 		$1.85M Buy
49,731
+8,640
+21% +$279K ﹤0.01% 1588
2026
Q1 		$1.3M Buy
+41,091
New +$1.12M ﹤0.01% 1665

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Vanguard Asset Management's CLDX Position: Q3 2026 in Review

Vanguard Asset Management held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 49,731 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

Vanguard Asset Management first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.85M in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Vanguard Asset Management held 49,731 shares of Celldex Therapeutics worth $1.61M as of Q3 2026.
  • Vanguard Asset Management left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1662 holding.
  • Vanguard Asset Management first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Celldex Therapeutics position peaked at $1.85M in Q2 2026.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.